SecBot SecBot
SECBOTREPLAY Home › Report › ORIC

ORIC · ORIC Pharmaceuticals reported Q1 2026 net loss of $35.8M ($0.34/share),…

Oric Pharmaceuticals, Inc. · 8-K filed May 4, 2026 at 16:10 ET

At the news

MIXEDIMPACT 4/10

8-K filed May 4, 2026 at 16:10 ET

ORIC Pharmaceuticals reported Q1 2026 net loss of $35.8M ($0.34/share), missing consensus estimates of $0.31/share by 9.7%, as R&D spending increased to $31.4M. However, the company announced selection of rinzimetostat RP3D and positive clinical data, with cash of $419.7M funding operations into 2H 2028.

  • Net loss per share $(0.34) vs consensus $(0.31) (EPS miss of ~9.7%)
  • Q1 2026 net loss $35.8M vs $30.0M in Q1 2025, driven by higher R&D costs
  • Cash, cash equivalents and investments $419.7M as of March 31, 2026
  • R&D expenses $31.4M, up 27.5% YoY due to advancement of rinzimetostat and enozertinib

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access